^
Association details:
| Biomarker: | EGFR negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anlotinib Hydrochloride as second-line therapy in elderly patients with EGFR wild-type lung adenocarcinoma who refused chemotherapy: an open, single-arm, single-center clinical trial
Excerpt:
...Provide detectable specimens (tissue or cancerous pleural effusion) for genotyping before enrollment, and the patients should be with negative EGFR, ALK, and ROS1 gene test results; 5. ...
Trial ID:
Source:
Title:
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
Excerpt:
...Detection of genotypes by providing detectable specimens (tissue) prior to enrollment: patients with negative EGFR mutation, or ALK rearrangement test results....
Trial ID:
More C2 evidence
Source:
Title:
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
Excerpt:
...Patients must provide detectable specimen (from tumor tissue or hydrothorax) before participating, who negative in EGFR&ALK can participate or who positive in EGFR&ALK, have or have...
Trial ID:
Source:
Title:
A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer
Excerpt:
...Patients with negative EGFR, ALK and ROS1 gene test results;...
Source:
Title:
Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Excerpt:
...- Diagnosed as locally advanced and / or metastatic non-squamous non-small cell lung adenocarcinoma (NSCLC) by cytology or histology; Provide detectable specimens (tissue or blood) for genotyping before enrollment, and the patients should be with negative EGFR, ALK and ROS1 gene test results, and without prior systemic therapy;...
Trial ID:
Source:
Title:
Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC
Excerpt:
...Provide detectable specimens (tissue or cancerous pleural effusion) for genotyping before enrollment, and the patients should be with negative EGFR, ALK, and ROS1 gene test results;...
Trial ID:
Source:
Title:
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Excerpt:
...- Negative in EGFR&ALK&ROS1...
Trial ID:
Source:
Title:
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Excerpt:
...Provide detectable specimens (tissue or cancerous pleural effusion) for genotyping before enrollment, and the patients should be with negative EGFR, ALK, and ROS1 gene test results;...
Trial ID:
Less C2 evidence
Source:
Title:
A multicenter, randomized, phase II trial of anlotinib plus docetaxel versus docetaxel in EGFR-negative NSCLC patients after progression on first-line platinum-base chemotherapy: ALTER-L018
Published date:
05/19/2021
Excerpt:
In group A and B, ORR and DCR were 32.14% versus 8.11%(p = 0.042), 82.12% versus 54.05%(p = 0.29), respectively….combination of anlotinib and docetaxel showed clinical benefit in EGFR-negative NSCLC patients in terms of PFS, ORR...
Secondary therapy:
docetaxel
DOI:
10.1200/JCO.2021.39.15_suppl.e21186
Trial ID:
Source:
Title:
166P - First-line anlotinib-based combination treatment for patients with advanced non-small cell lung cancer: A three arms, prospective study
Published date:
03/17/2021
Excerpt:
In this open-label, three arm, prospective study, advanced NSCLC patients...with EGFR mutation negative, the treatment regimen was anlotinib in combination with chemotherapy (Cohort B)….In Cohort B, ORR was 60.0%, while DCR was 96.7%. Median PFS was 13.3 months, and 12-month PFS rate was 55.5%....For EGFR-mutated negative patients, anlotinib combines with chemotherapy or sintilimab also may be a promising first-line treatment.
Secondary therapy:
Chemotherapy
Trial ID:
